Hidradenitis suppurativa
ICD-10 L73.2 · ICD-11 ED92.0

Hidradenitis Suppurativa in a Pediatric Patient Younger Than 18

Hidradenitis suppurativa presenting in a patient younger than 18 years follows a management framework broadly aligned with the adult approach, but with specific considerations that must guide therapy selection for this age group.

Clinical Scenario The patient is a pediatric individual (younger than 18 years) with hidradenitis suppurativa. Management strategies are similar to those for adults, with important age- and sex-specific restrictions shaping which therapeutic options are appropriate.
Treatment Approach (Partial Overview) The escalation pathway involves antibiotic combination therapy and biologic treatment options, with specific agents excluded based on patient age and sex. The complete regimen — including agent selection, sequencing, and the full set of pediatric caveats — is available in the structured protocol.

Full regimen details, dosing, and decision algorithm available via the protocol link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jaad.2019.02.067

Management strategies are similar to those for adults with some specific considerations outlined in Table VIII.

Clindamycin and rifampin in combination have been studied in HS more than most other antibiotics, typically with both used at a dose of 300 mg twice daily.

Adalimumab at the approved HS dosing is recommended to improve disease severity and quality of life in patients with moderate-to-severe HS.

Avoid tetracyclines in children younger than 9 years and acitretin in female patients during the childbearing years.

View source ↗